Commentary: Theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: The traditional model, segregated flow model, and QGut model

Drug Metabolism and Disposition

Volumn 40, Issue 10, 2012, Pages 1869-1877

  Pang, K Sandy ^a   Chow, Edwin C Y ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITY; FLOW RATE; INTERMETHOD COMPARISON; INTESTINE ABSORPTION; LIVER METABOLISM; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEMBRANE PERMEABILITY; NOTE; PRIORITY JOURNAL; TRANSPORT KINETICS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; ENTEROCYTES; ENTEROHEPATIC CIRCULATION; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84866461807     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045872     Document Type: Note

References (58)

1. Abuasal BS, Bolger MB, Walker DK, and Kaddoumi A (2012) In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol Pharm 9:492-504.
2. Agoram B, Woltosz WS, and Bolger MB (2001) Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 (Suppl 1):S41-S67. (Pubitemid 32905355)
3. Badhan R, Penny J, Galetin A, and Houston JB (2009) Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 98:2180-2197.
4. Bolger MB, Lukacova V, and Woltosz WS (2009) Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 11:353-363.
5. Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, et al. (2010) Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 7:1596-1607.
6. Chalasani N, Gorski JC, Patel NH, Hall SD, and Galinsky RE (2001) Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 34:1103-1108. (Pubitemid 33096581)
7. Chen J and Pang KS (1997) Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. J Pharmacol Exp Ther 280:24-31. (Pubitemid 27171383)
8. Chow EC and Pang KS (2013) Why we need PBPK modeling to examine intestine and liver oral drug absorption. Curr Drug Metab, in press.
9. Chow EC, Durk MR, Cummins CL, and Pang KS (2011) 1α,25- Dihydroxyvitamin D3 upregulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther 337:846-859.
10. Cong D, Doherty M, and Pang KS (2000) A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 28:224-235. (Pubitemid 30069008)
11. Cong D, Fong AK, Lee R, and Pang KS (2001) Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. Drug Metab Dispos 29:1539-1547. (Pubitemid 33111586)
12. Corti G, Maestrelli F, Cirri M, Furlanetto S, and Mura P (2006) Development and evaluation of an in vitro method for prediction of human drug absorption I. Assessment of artificial membrane composition. Eur J Pharm Sci 27:346-353. (Pubitemid 43143260)
13. Darwich AS, Neuhoff S, Jamei M, and Rostami-Hodjegan A (2010) Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab 11:716-729.
14. de Lannoy IA and Pang KS (1986) Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. Drug Metab Dispos 14:513-520.
15. de Lannoy IA and Pang KS (1987) Effect of diffusional barriers on drug and metabolite kinetics. Drug Metab Dispos 15:51-58.
16. Doherty MM and Pang KS (2000) Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm Res 17:291-298. (Pubitemid 30225132)
17. Eeckhoudt SL, Horsmans Y, and Verbeeck RK (2002) Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32:975-984. (Pubitemid 35347005)
18. Fan J, Chen S, Chow EC, and Pang KS (2010) PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 11:743-761.
19. Fang C and Zhang QY (2010) The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene. J Pharmacol Exp Ther 334:156-163.
20. Fromm MF, Busse D, Kroemer HK, and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801. (Pubitemid 26334275)
21. Galetin A, Gertz M, and Houston JB (2010) Contribution of intestinal cytochrome P450- mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25:28-47.
22. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
23. Gertz M, Houston JB, and Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633-1642.
24. Granger DN, Richardson PD, Kvietys PR, and Mortillaro NA (1980) Intestinal blood flow. Gastroenterology 78:837-863. (Pubitemid 10111952)
25. Hendriksen BA, Felix MV, and Bolger MB (2003) The composite solubility versus pH profile and its role in intestinal absorption prediction. AAPS PharmSci 5:E4.
26. Kadono K, Akabane T, Tabata K, Gato K, Terashita S, and Teramura T (2010) Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230-1237.
27. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
28. Liu S, Tam D, Chen X, and Pang KS (2006) P-Glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation: induction studies with pregnenolone-16α- carbonitrile. Drug Metab Dispos 34:1468-1479. (Pubitemid 44285387)
29. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, and Wang GJ (2010) Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38:1779-1784.
30. Lledó-García R, Nácher A, Casabó VG, and Merino-Sanjuán M (2011) A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. Drug Metab Dispos 39:294-301.
31. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, and Watkins PB (1995) The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 57:16-24.
32. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, and Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1-9. (Pubitemid 34833182)
33. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24. (Pubitemid 26279216)
34. Pang KS (2003) Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31:1507-1519.
35. Pang KS and Durk MR (2010) Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 37:591-615.
36. Pang KS and Gillette JR (1979) Sequential first-pass elimination of a metabolite derived from a precursor. J Pharmacokinet Biopharm 7:275-290. (Pubitemid 9225442)
37. Pang KS, Cherry WF, and Ulm EH (1985) Disposition of enalapril in the perfused rat intestine liver preparation: absorption, metabolism and first pass effect. J Pharmacol Exp Ther 233: 788-795. (Pubitemid 15024450)
38. Pang KS, Maeng HJ, and Fan J (2009) Interplay of transporters and enzymes in drug and metabolite processing. Mol Pharm 6:1734-1755.
39. Pang KS, Morris ME, and Sun H (2008) Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol 60:1247-1275.
40. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653. (Pubitemid 8253670)
41. Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, and Kimura RE (2008) Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Dispos 36:1097-1101. (Pubitemid 351717467)
42. Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, and Hall SD (2010) Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38:241-248.
43. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
44. Sun H and Pang KS (2009) Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study. Drug Metab Dispos 37:187-202.
45. Sun H and Pang KS (2010) Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 27:1237-1254.
46. Suzuki H and Sugiyama Y (2000a) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
47. Suzuki H and Sugiyama Y (2000b) Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin Liver Dis 20:251-263.
48. Tam D, Tirona RG, and Pang KS (2003) Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31:373-383. (Pubitemid 36378514)
49. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A mediated metabolism. Clin Pharmacol Ther 59:491-502.
50. Valentin J (2002) Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. Pergamon, Oxford.
51. Wu B (2012) Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. J Pharm Sci 101:1281-1301.
52. Xu X, Hirayama H, and Pang KS (1989) First-pass metabolism of salicylamide. Studies in the once-through vascularly perfused rat intestine-liver preparation. Drug Metab Dispos 17:556-563. (Pubitemid 19244921)
53. Yan GZ, Generaux CN, Yoon M, Goldsmith RB, Tidwell RR, Hall JE, Olson CA, Clewell HJ, Brouwer KL, and Paine MF (2012) A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair. Drug Metab Dispos 40:6-17.
54. Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, and Rostami- Hodjegan A (2006) Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol 20:842-849. (Pubitemid 44622750)
55. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684. (Pubitemid 47578116)
56. Zhang X, Quinney SK, Gorski JC, Jones DR, and Hall SD (2009) Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 37:1587-1597.
57. Zhu Y, D'Agostino J, and Zhang QY (2011) Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos 39:939-943.
58. Zhu C, Jiang L, Chen TM, and Hwang KK (2002) A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 37:399-407. (Pubitemid 34465549)